Experts spotlight the variety of breast cancer research being presented at the 2026 ESMO Congress.
News|Articles|January 28, 2026
- Vol.27/No.3
- Volume 27
Ultrasensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
Author(s)Jax DiEugenio
Fact checked by: Chris Ryan, Ron Panarotti
The emergence of ultrasensitive ctDNA and CSF testing may help alter monitoring strategies and adaptive clinical trial designs in metastatic breast cancer.
Advertisement
Advertisement
Ultrasensitive circulating tumor DNA (ctDNA) monitoring is increasingly reframing how metastatic breast cancer clinical trials are designed and how treatment decisions may be timed, shifting the focus from reacting to radiographic progression to intervening at the earliest molecular signs of resistance.1
Related to this article
The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.
The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.
FDA Approves Denosumab Biosimilar for Skeletal-Related Events, GCTB, and Hypercalcemia of Malignancy
Denosumab-adet (Degevma) is FDA approved as an Xgeva biosimilar for SRE prevention in myeloma and bone metastases, giant cell tumor of bone, and HCM.
Researchers at Wake Forest University School of Medicine identified a protein that may help breast cancer spread to the brain and evade immune defenses.
Benjamin Weinberg, MD, discusses the FDA approval of daraxonrasib, RASolute 302 survival data, safety considerations, and future RAS-targeted therapies in pancreatic cancer.
Advertisement
Advertisement